A Phase 3 trial of firmonertinib did not meet its main goal in a hard-to-treat lung cancer subtype, though the drug caused fewer serious side effects than chemotherapy.

A phase 3 trial found that adding Imdelltra to Imfinzi maintenance improved survival in extensive-stage small cell lung cancer, while another drug's application was pulled. Here's what patients should know.

September brought new options for breast, lung, kidney, bile duct, skin and neuroendocrine cancers, plus a brain tumor scan and easier lung cancer treatment.

Ivonescimab outperformed Keytruda, a new myeloma drug lowered progression risk by 60% and more: the biggest phase 3 cancer results of September 2026.

Replacing two cycles of intensive chemotherapy with Blincyto raised four-year event-free survival to 83% from 70.3% in children with high-risk B-cell ALL, with far fewer infections.

In a trial of 2,175 people with early HER2-positive breast cancer, 43.8% had no invasive cancer left after 12 weeks of a lighter regimen, and certain tumor features predicted who was most likely to respond.

Median progression-free survival reached 24.9 months with Tukysa plus Herceptin and Perjeta versus 16.3 months with placebo plus Herceptin and Perjeta.

In a study of more than 250,000 older adults presented at ASTRO 2026, people with depression who started talk therapy within a week of their cancer diagnosis had a 27% lower risk of dying from their cancer. But most people with depression received no mental health treatment at all.